AUS: (617) 38560661 | US: (855) 950-4567 | E-mail:

Click here to read the original article.

In a clinical study with potty-trained children who still wet the bed, Urox showed statistically significant improvement for occasional bedwetting.

Nocturnal enuresis or ‘bedwetting’ is a form of nighttime urinary incontinence occurring in younger children. Researchers point to several causes, from reduced bladder capacity, and/or an overactive bladder to genetics and even obstructive sleep apnea.

According to the National Sleep Foundation, 10% of children wet the bed. In an effort to help stop children from extended bedwetting and assist families through a successful potty-training period, Seipel Group took their Urox formulation and created a dose for children. The children’s version, called Bedtime Buddy, was the subject of a study recently published Phytomedicine. This year, Urox won NutraIngredientsBotanical of The Year award.

The study

The randomized double-blind placebo-controlled trial evaluated the efficacy of Urox (Bedtime Buddy) against placebo for the treatment of nocturnal enuresis in children aged 6–14 years old over an eight week period. Forty one children completed the trial with an attrition rate of 16%. There were more males (64%) compared to females (35%) and the mean age was 8.6 years.

The participants were randomized via computerised random-number generation at study enrollment to receive one or two oral capsules in the morning of either Urox (Bedtime Buddy) or placebo. Each capsule contains 420 mg of a proprietary blend of Cratevox (Crataeva nurvala L.; Capparidaceae; Varuna) stem bark extract standardized for 1.5% lupeol: non-standardized Equisetum arvense L. (Equisetaceae; Horsetail) stem extract; and non-standardized Lindera aggregata Sims.


The primary outcome found that there was a statistically significant reduction in nocturnal enuresis (p = 0.034; CI 0.086–2.095) and between groups using longitudinal analysis (p = 0.04, Coefficient -1.12, CI 95% -2.20 – -0.04). In the secondary outcomes, urinary urgency reduced statistically significantly for the intervention (p = 0.002; a reduction of 18.3% difference for Bedtime Buddy compared to an increase of 3.7% for the placebo).

“Overall, 41.7% of children improved with Urox (Bedtime Buddy) indicating a good reduction in nocturnal enuresis. This percentage indicates that 41.7% of the participants on Bedtime Buddy experienced between 30 and 100% improvement from their bedwetting. Urox (Bedtime Buddy) completely stopped daily urinary incontinence or wetting throughout the day and significantly reduced urinary urgency and soiled underwear,” the authors concluded.

Source: Phytomedicine
Vol 93, Dec 2021,
A randomised, double-blind, placebo-controlled clinical trial found that a novel herbal formula Urox (Bedtime Buddy) assisted children for the treatment of nocturnal enuresis”
Authors: J. Schloss et al.